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ABSTRACT
Objective: To explore whether systematic reviewers
selectively include trial effect estimates in meta-
analyses when multiple are available, and what impact
this may have on meta-analytic effects.
Design: Cross-sectional study.
Data sources: We randomly selected systematic
reviews of interventions from 2 clinical specialties
published between January 2010 and 2012. The first
presented meta-analysis of a continuous outcome in
each review was selected (index meta-analysis), and
all trial effect estimates that were eligible for
inclusion in the meta-analysis (eg, from multiple
scales or time points) were extracted from trial
reports.
Analysis: We calculated a statistic (the Potential
Bias Index (PBI)) to quantify and test for evidence of
selective inclusion. The PBI ranges from 0 to 1;
values above or below 0.5 are suggestive of selective
inclusion of effect estimates more or less favourable
to the intervention, respectively. The impact of any
potential selective inclusion was investigated by
comparing the index meta-analytic standardised
mean difference (SMD) to the median of a randomly
constructed distribution of meta-analytic SMDs
(representing the meta-analytic SMD expected when
there is no selective inclusion).
Results: 31 reviews (250 trials) were included. The
estimated PBI was 0.57 (95% CI 0.50 to 0.63),
suggesting that trial effect estimates that were more
favourable to the intervention were included in meta-
analyses slightly more often than expected under a
process consistent with random selection; however,
the 95% CI included the null hypothesis of no
selective inclusion. Any potential selective inclusion
did not have an important impact on the meta-
analytic effects.
Conclusion: There was no clear evidence that
selective inclusion of trial effect estimates
occurred in this sample of meta-analyses. Further
research on selective inclusion in other clinical
specialties is needed. To enable readers to assess
the risk of selective inclusion bias, we recommend
that systematic reviewers report the methods used
to select effect estimates to include in meta-
analyses.
INTRODUCTION
Systematic reviews and meta-analyses of
healthcare intervention trials can contribute
to improved patient care by providing valid
and reliable information for healthcare
decision-making.1 However, the validity of sys-
tematic review ﬁndings can be compromised
by challenges with undertaking meta-analysis.
One challenge arises when there are mul-
tiple effect estimates in a trial report which
could be included in a particular meta-
analysis. For example, systematic reviewers
performing a meta-analysis of depression
scores may encounter mean differences for
two depression scales at three time points.2 3
Strengths and limitations of this study
▪ We predefined our methods in a published
protocol, used validated search strategies to
identify eligible reviews and included a randomly
selected sample of reviews.
▪ Our estimates of the Potential Bias Index and the
impact of potential selective inclusion on the
meta-analytic effects were robust to several
assumptions and statistical approaches.
▪ We only examined two clinical specialties (with
two-thirds of the index meta-analyses focused
on pain or depression), so our results may have
limited generalisability to systematic reviews of
other conditions.
▪ Our findings may have been influenced by
incomplete reporting by systematic reviewers, as
we used the methods reported in the review pro-
tocols to select trial effect estimates; however,
other selection methods may have been
assumed but not documented at the protocol
stage.
▪ We only investigated selective inclusion of com-
pletely reported effect estimates; the set of effect
estimates that were actually considered by the
systematic reviewers may have been larger,
encompassing both reported and unreported
estimates (in the case of the latter, obtained dir-
ectly from the triallists).
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In such instances, it is preferable that the selection of
effect estimates to include in the meta-analysis is based
on predeﬁned clinical or methodological rationale (eg,
selecting the mean difference of the depression scale
with the best measurement properties). However, in
some cases, the selection may be based on the nature or
direction of the estimates themselves;4 this is analogous
to when triallists perform multiple analyses of the same
outcome, yet only report that which is most favourable.
This data-driven selection by systematic reviewers is
known as selective inclusion, and has the potential to
bias meta-analytic effects.
Concerns about the potential for selective inclusion of
trial effect estimates have been previously raised. In a
study of 19 Cochrane reviews including 83 trials, a third
of the trial reports had data for multiple measurement
scales, intervention/control groups or time points that
could have been included in a particular meta-analysis.
There was potential for large and clinically important
variability in the resulting meta-analytic effects depend-
ing on which trial effect estimates were included.3
However, there has been no empirical investigation of
whether systematic reviewers selectively include trial
effect estimates in meta-analyses when multiple estimates
are available, or the potential impact of selective inclu-
sion on meta-analytic effects.5 Therefore, it is unclear to
what extent users of systematic reviews should be con-
cerned about selective inclusion.
We investigated whether selective inclusion of trial
effect estimates occurred in a sample of meta-analyses,
and what impact this might have on meta-analytic
effects.
METHODS
The study protocol is published elsewhere.6 An overview
of the methods is provided here, and deviations from
the planned methods are presented in online supple-
mentary appendix S1.
Eligibility criteria, searching and selection methods
We included systematic reviews meeting the following
criteria: Cochrane or non-Cochrane systematic review
published between January 2010 and January 2012;
focusing on any intervention for rheumatoid arthritis
(RA), osteoarthritis (OA), depressive disorders or
anxiety disorders; written in English; reporting refer-
ences of all included trials; and reporting, for at least
one meta-analysis of a continuous outcome, the
summary statistics (eg, means, SDs, sample sizes) or
effect estimate and its precision for each included trial,
and the meta-analytic effect estimate and its precision.
We excluded systematic reviews which reported no
meta-analyses of continuous outcomes, included non-
randomised studies in all meta-analyses of continuous
outcomes or used non-standard meta-analytical methods
(eg, Bayesian, multiple treatments or individual patient
data meta-analyses).
We selected the conditions RA/OA and depressive/
anxiety disorders because we wanted to explore whether
the existence of a core outcome measurement set for
RA and OA trials7 8 impacted on selective inclusion.
Core outcome measurement sets are lists of measure-
ment scales recommended for use in trials and system-
atic reviews of a particular health condition, and are
designed to increase consistency in scale selection.9
We therefore expected selective inclusion to be less
common in reviews with a core outcome measurement
set (RA and OA reviews) compared with reviews without
a core outcome measurement set (depressive/anxiety
disorders reviews). Depressive/anxiety disorders reviews
were selected because of our familiarity with the meas-
urement scales typically used in this specialty. Further,
we only focused on continuous outcomes because there
is greater scope for multiplicity of effect estimates for
continuous rather than dichotomous outcomes in these
clinical specialties (eg, arising from multiple measure-
ment scales, adjusted vs unadjusted means, subscale
scores).
We searched the Cochrane Database of Systematic
Reviews and MEDLINE (PubMed interface), limiting
the publication date from 1 January 2010 to 31 January
2012. Search strategies are provided in online supple-
mentary appendix S2. One author (MJP) screened all
titles and abstracts and retrieved the full-text reports of
potentially eligible records. The citations of full-text
reports were randomly sorted (using the random
number generator in Microsoft Excel), and one author
(MJP) then screened the full-text reports until at least
10 of each type of review (Cochrane RA/OA,
non-Cochrane RA/OA, Cochrane depressive/anxiety dis-
order and non-Cochrane depressive/anxiety disorder)
meeting the eligibility criteria were identiﬁed. Screening
ceased once 44 eligible reviews were included. Any difﬁ-
culties in determining eligibility were resolved by discus-
sion with a second author ( JEM). The ﬁrst presented
meta-analysis of an effect measure for a continuous
outcome (either the mean difference or standardised
mean difference (SMD)) in each review was selected for
inclusion (which we denote the ‘index meta-analysis’).
The index meta-analysis may have been identiﬁed from
the abstract, summary of ﬁndings table or results section
of the review, depending on where the meta-analytic
effect estimate was ﬁrst reported in the publication.
Data extraction
Published protocols of included reviews and reports of
trials included in the index meta-analyses were retrieved.
One author (MJP) extracted data from all review proto-
cols, reviews and trial reports using a standardised pilot
tested form. A second author (MC) independently
extracted data from a random sample of 14 reviews,
including the corresponding review protocols and
included trials, to assess accuracy of the extraction.
Discrepancies between the two sets of extracted data
were resolved via discussion.
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From each review protocol and review, we extracted
descriptions of:
▸ The clinical condition, types of interventions and
comparisons, outcomes of interest and funding
source of the review.
▸ Any eligibility criteria to select effect estimates to
include in the index meta-analysis. Eligibility criteria
comprised lists of measurement scales, intervention/
control groups, time points and analyses that were eli-
gible for inclusion (eg, a statement that eligible
depression scales included only the Hamilton Rating
Scale for Depression (HRSD), the Montgomery-
Asberg Depression Rating Scale (MADRS) and the
Beck Depression Inventory (BDI)).
▸ Any decision rules to select effect estimates to include
in the index meta-analysis. Decision rules comprised
strategies to either select one effect estimate or
combine effect estimates when multiple were avail-
able (eg, a statement that the HRSD would be
selected over the BDI if data for both were available,
or that data from two active intervention arms in mul-
tiarm trials would be combined for inclusion in a
pairwise meta-analysis).
We extracted from the trial reports outcome data that
could potentially be included in the index meta-analyses,
according to the eligibility criteria and decision rules
that were prespeciﬁed in the review protocol, and how
the outcome was speciﬁed in the review (eg, ‘depression
score’ or ‘HRSD depression score at the end of treat-
ment’). For reviews without a publicly available protocol,
we assumed that no eligibility criteria and decision rules
were prespeciﬁed, even if some were reported in the
published review (‘worst-case scenario’ assumption), and
extracted all outcome data based on how the outcome
was speciﬁed in the review. For example, if the index
meta-analysis was speciﬁed as ‘mean difference in BDI
scores’ and there was no review protocol, we extracted
from trials all results for the BDI (eg, at all time points,
ﬁnal and change from baseline values, unadjusted and
covariate-adjusted analyses, regardless of whether deci-
sion rules for these measures/analyses were stated in the
published review), but no results for any other depres-
sion scales. ‘Outcome data’ included summary statistics
(eg, means, SDs, sample sizes) or effect estimate (eg,
mean difference) and some measure of precision (eg,
SE, 95% CI); or both if available. The predeﬁned
methods which we used to extract trial outcome data are
summarised in online supplementary appendix S3. We
only extracted trial outcome data that were completely
reported, deﬁned as reporting sufﬁcient data for inclu-
sion in a meta-analysis (ie, reporting of an effect esti-
mate and a measure of precision, or summary statistics
that enable calculation of these).10 Unpublished data
(eg, missing SDs) were not sought from triallists.
Statistical analyses
All analyses were conducted using Stata V.12 (Stata
Corp. Stata Statistical Software: Release 12 [program].
College Station, Texas, USA: StataCorp LP, 2011). Index
meta-analyses that included no trials with multiplicity of
effect estimates were excluded from all analyses because
they could not contribute to the assessment of selective
inclusion. Characteristics of the index meta-analyses
were summarised using frequencies and percentages for
binary outcomes, and medians (with IQRs and ranges)
for continuous outcomes. The frequencies and percen-
tages of review protocols and reviews reporting eligibility
criteria and decision rules to select trial effect estimates
were calculated.
We calculated a statistic (the Potential Bias Index
(PBI)) to quantify and test for evidence of selective
inclusion. Mathematical details of the construction of
the PBI are available in the study protocol,6 and a
worked example is provided in online supplementary
appendix S4. In brief, this index is based on ordering
effect estimates in each trial based on their magnitude
and direction of effect, and determining the position
within that order of the effect estimate selected for
inclusion in the index meta-analyses. The PBI is the
weighted average rank position of the selected effect
estimates, where the weights are the inverse of the
number of effect estimates available per trial. This
weighting system therefore attributes greater priority to
the rank positions of effect estimates where there are a
larger number of effect estimates to choose from. To
enable ranking of effect estimates that were measured
using different measurement scales, all effect estimates
were expressed in terms of SD units by dividing the
mean difference on the raw measurement scale by the
pooled SD (SMDs).11 Further, the direction of interven-
tion effects was standardised, so that larger negative
values represented effects that are more favourable to
the intervention.
The PBI ranges from 0 to 1. When the effect estimate
that is most favourable to the intervention in each of the
trials is always selected for inclusion, the PBI will have
the value 1. Conversely, the PBI will have the value of 0
when the effect estimate that is least favourable to the
intervention is always selected. Several methods for
selecting effect estimates are acceptable in terms of not
introducing bias, including (1) randomly selecting effect
estimates, (2) selecting effect estimates based on some
clinical or methodological rationale or (3) selecting the
median effect estimate. If selection methods 2 and 3 are
employed across the trials, we expect that the distribu-
tion of selected effect estimates would be consistent with
what we would observe under purely random selection,
so on average, the selected effect estimates would be at
the middle rank position and the PBI would take the
value of 0.5. A PBI of 0.5 therefore suggests that there is
no selective inclusion of the most or least favourable
effect estimates. We constructed a statistical test based
on the PBI to test whether the observed selection of
effect estimates is consistent with randomness of selec-
tion.6 Conﬁdence limits (95%) for the PBI were
obtained by bootstrap resampling.12
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We also investigated the impact of any potential select-
ive inclusion of trial effect estimates on the magnitude
of the resulting meta-analytic SMDs. For each
meta-analysis, we calculated all possible meta-analytic
SMDs from all combinations of available trial effect esti-
mates. When the number of possible combinations was
prohibitively large to calculate all combinations (ie,
>30 000), we generated a random sampling distribution
of 5000 meta-analytic SMDs. Each meta-analytic SMD
was created by randomly selecting (with equal probabil-
ity) an effect estimate for inclusion from each trial com-
parison, and meta-analysing the chosen effects. For each
distribution of generated meta-analyses, we calculated
(1) the percentile rank of the index meta-analytic SMD;
(2) the median of all possible meta-analytic SMDs,
which represented the median of a distribution where
trial effect estimates were not selectively included and
(3) the difference between the index meta-analytic SMD
and the median meta-analytic SMD. When the differ-
ence between the index and median meta-analytic SMD
is minimal, any potential selective inclusion had limited
impact on the meta-analytic effect. Non-parametric sta-
tistics were used to describe these differences. We also
meta-analysed these differences using a random-effects
meta-analysis model, with the meta-analytic weights
based on the variance of the index meta-analytic SMD
estimate and the between-trial variability estimated using
DerSimonian and Laird’s13 method of moments
estimator.
We performed prespeciﬁed subgroup analyses to
explore whether the availability of a systematic review
protocol, and a core outcome measurement set for the
clinical condition of the review, modiﬁed the PBI. We
ﬁtted a post hoc linear regression model to explore
whether the PBI was modiﬁed by the number of avail-
able effect estimates in a trial. We undertook a series of
prespeciﬁed and post hoc sensitivity analyses, the details
of which are provided in online supplementary appen-
dix S5.
RESULTS
Search results and data extraction discrepancies
Searching yielded a total of 2590 title and abstract
records which were screened. A full-text article was
retrieved for 264 records. Of these, 44 systematic reviews
met the eligibility criteria, but only 31 included trials with
multiplicity of effect estimates and thus could contribute
to the assessment of selective inclusion (ﬁgure 1).
Of the subset of 14 of 44 reviews where data were
extracted by two authors independently, 8 (26%) were
in the ﬁnal included sample of 31 reviews. Comparison
of the double data extraction identiﬁed no errors in the
classiﬁcation of review text as an ‘eligibility criterion’ or
‘decision rule’, and the summary statistics and effect esti-
mates extracted were consistent except for in one review
where the second reviewer missed a decision rule in the
review protocol, which resulted in the extraction of
three ineligible trial effect estimates. Hence, no modiﬁ-
cations to the ﬁrst reviewers’ extraction were required.
Characteristics of included meta-analyses
Of the 31 index meta-analyses, 4 were from Cochrane
RA or OA reviews, 11 were from non-Cochrane RA or
OA reviews, 9 were from Cochrane depressive or anxiety
disorder reviews, and 7 were from non-Cochrane depres-
sive or anxiety disorder reviews. Twelve (39%)
meta-analyses were in Cochrane reviews with a protocol
published between 2006 and 2011 (table 1). The most
common outcome domains analysed in the index
meta-analyses were depression (12 meta-analyses) or
pain (8 meta-analyses). Nine other outcome domains
were analysed in at least one meta-analysis. There was an
approximately equal distribution of index meta-analyses
that were labelled primary versus non-primary outcomes.
The majority of index meta-analyses pooled SMDs, were
ﬁtted using a random-effects model, examined a
placebo/no intervention controlled comparison and
investigated the efﬁcacy/effectiveness of a non-
pharmacological intervention. Two (6%) reviews were
funded by the pharmaceutical industry (table 1). There
were a total of 250 trials included in the 31 index
meta-analyses, with a median of 6 trials (IQR 3–10;
range 2–28) per meta-analysis.
Multiplicity of effect estimates in trial reports and
methods to select effect estimates
In 118 (47%) trials, there were multiple effect estimates
that were eligible for inclusion in a particular
meta-analysis. In these trials with multiplicity, there was a
median of 3 (IQR 2–4; range 2–12) eligible effect esti-
mates per trial. Details of the types of multiplicity (eg,
multiple scales, time points) are available in online sup-
plementary table S1. Descriptive statistics at the
meta-analysis level were reﬂective of those at the trial
level; per meta-analysis, a median of 50% of trials had
multiplicity (IQR 22–67%; range 14–100%).
The types of methods to select effect estimates to
include in meta-analyses that were documented in the
review protocols and reviews varied considerably (see
online supplementary table S2). For example, of 12
review protocols, only 2 (17%) included a prespeciﬁed
decision rule to select measurement scales while 7
(58%) included a prespeciﬁed decision rule to select
time points.
Evidence of selective inclusion of trial effect estimates
The estimated PBI was 0.57 (95% CI 0.50 to 0.63; two-
tailed p value of 0.10). This suggests that trial effect esti-
mates that were more favourable to the intervention
were included in meta-analyses slightly more often than
expected under a process consistent with random selec-
tion; however, the 95% CI included the null hypothesis
of no selective inclusion. The PBI was not modiﬁed by
the availability of a systematic review protocol or a core
outcome measurement set for the clinical condition of
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the review (table 2), and was robust to the series of sensi-
tivity analyses (see online supplementary table S3). The
post hoc linear regression exploring the relationship
between the number of available effect estimates and
the PBI suggested that for every unit increase in the
number of effect estimates, the PBI was predicted to
reduce by −0.014 (95% CI −0.019 to −0.009; see online
supplementary ﬁgure S1). For example, the predicted
PBI was 0.60 (95% CI 0.59 to 0.61) when there were two
available effect estimates, and 0.54 (95% CI 0.51 to 0.57)
when there were six effect estimates.
Impact of potential selective inclusion of trial effect
estimates on meta-analytic SMDs
The median number of possible meta-analytic SMDs
arising from meta-analysing all combinations of trial
effect estimates was 8 (across the 31 meta-analyses);
however, there was wide variation in this number (IQR
3–576, range 2–1.8 trillion; table 3). The median per-
centile rank of the index meta-analytic SMD was 0.74
(IQR 0.20–1; range 0–1; note that when the percentile
rank is 1, the index meta-analytic SMD was the most
favourable of all possible meta-analytic SMDs). For most
Figure 1 Flow diagram of
identification, screening and
inclusion of systematic reviews.
RCT, randomised controlled trial.
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meta-analyses, the range of possible meta-analytic SMDs
which could be calculated (each ﬁtted using a random-
effects model) was narrow. The median difference
between the largest and smallest possible meta-analytic
SMD was 0.11 SD units (IQR 0.03–0.19; range 0–0.43;
table 3 and ﬁgure 2).
Table 1 Characteristics of index meta-analyses (n=31)
Characteristics n (%)*
Review protocol status
Published in the Cochrane Database of Systematic Reviews 12 (39)
Unavailable or no mention that a review protocol was used 19 (61)
Clinical condition
Rheumatoid arthritis or osteoarthritis 15 (48)
Depressive or anxiety disorder 16 (52)
Trials
Number of trials in the meta-analysis, median (IQR) 6 (3, 10)
Outcome domain
Depression 12 (39)
Pain 8 (26)
Function 2 (6)
Swollen joint count 2 (6)
Other (anxiety, obsessive compulsive symptoms, aerobic capacity, fatigue, physical activity, quality of life,
range of motion)
7 (23)
Outcome label
Primary 16 (52)
Non-primary (secondary or not labelled) 15 (48)
Effect measure
Mean difference 4 (13)
Standardised mean difference 27 (87)
Meta-analysis model
Fixed-effects 5 (16)
Random-effects 24 (77)
Not reported† 2 (6)
Type of comparison
Placebo/no intervention controlled comparison 29 (94)
Head-to-head comparison 2 (6)
Type of active intervention
Pharmacological 12 (39)
Non-pharmacological 19 (61)
Source of funding for systematic review
Pharmaceutical industry 2 (6)
Non-industry (governmental agency or other not-for-profit organisation) 11 (35)
No funding 9 (29)
Not reported 9 (29)
Meta-analysis specification
RA/OA meta-analyses n=15
Defined by scale
Yes (eg, Health Assessment Questionnaire score) 3 (20)
No (eg, disability) 12 (80)
Defined by time point
Yes (eg, pain at 6 weeks) 4 (27)
No (eg, pain) 11 (73)
Depressive/anxiety disorder meta-analyses n=16
Defined by scale
Yes (eg, Beck Depression Inventory score) 4 (25)
No (eg, depression score) 12 (75)
Defined by time point
Yes (eg, anxiety at 3 months) 9 (56)
No (eg, anxiety) 7 (44)
*All values given as n (%) except where indicated.
†Meta-analysis model not stated and unclear because both a fixed-effects and random-effects model produced the same SMD and 95% CI.
OA, osteoarthritis; RA, rheumatoid arthritis; SMD, standardised mean difference.
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The impact of any potential selective inclusion on the
meta-analytic SMDs was negligible. The median of the
differences between the index meta-analytic SMD and
the median of all its possible meta-analytic SMDs (ie,
the SMD expected when there is no selective inclusion)
was −0.01 SD units (IQR −0.05 to 0.01; range −0.20 to
0.16). Meta-analysing these differences using a random-
effects model yielded a pooled difference of −0.004 SD
units (95% CI −0.03 to 0.03; I2=0%; ﬁgure 3).
Recalculating all possible meta-analytic SMDs using a
ﬁxed-effects model yielded nearly identical results (see
online supplementary ﬁgure S2).
DISCUSSION
There was no clear evidence that systematic reviewers
selectively included trial effect estimates in this sample
of meta-analyses of interventions for RA, OA, and
depressive or anxiety disorders. The PBI was not modi-
ﬁed by the availability of a systematic review protocol or
a core outcome measurement set for the clinical condi-
tion of the review, and was robust to several assumptions.
Any potential selective inclusion did not have an import-
ant impact on the meta-analytic effects. To our knowl-
edge, no other study has investigated selective inclusion
of trial effect estimates in systematic reviews and its
potential impact on meta-analytic effects.
Strengths and weaknesses of the study
Our study has several strengths. We predeﬁned our
objectives and methods in a published protocol.6 We
used validated search strategies to identify eligible
reviews and included a randomly selected sample of
reviews. We included both Cochrane reviews and reviews
published in other sources to increase the generalisabil-
ity of results. Our estimates of the PBI and the impact of
potential selective inclusion on the meta-analytic SMDs
were robust to several assumptions and statistical
approaches.
There are some limitations of our study. We only
examined two clinical specialties (with two-thirds of the
index meta-analyses focused on self-reported pain or
depression), and we only included Cochrane and
MEDLINE indexed non-Cochrane reviews published in
English, so our results may have limited generalisability
to other types of systematic reviews. Our subgroup com-
parison of reviews with versus without a core outcome
measurement set is confounded by clinical specialty.
Our sample size calculation was based on estimating the
extent of multiplicity in trials rather than the magnitude
of selective inclusion bias, as power calculations for the
latter type of analysis do not yet exist. However, the
resulting CI for the magnitude of bias in the primary
analysis was narrow and conclusive, in that it excluded
an effect in the alternative direction (ie, the possibility
of selective inclusion of less favourable effects).
Screening of the systematic reviews and extraction of
74% of the data was completed by only one author.
However, we believe single screening is unlikely to have
biased our results because at the screening stage,
included trials had not been retrieved, so review inclu-
sion/exclusion decisions were unable to be inﬂuenced
by knowledge of the results in the trial reports. Further,
since the systematic reviews that were extracted by two
authors were randomly selected, we expect that the data
extraction error rate in the random sample (which was
very low) is representative of that of the entire sample.
Our ﬁndings may be inﬂuenced by the set of trial
effect estimates that we considered eligible for inclusion
in the meta-analyses. We used the methods reported in
the review protocols to select effect estimates; however,
other selection methods may have been assumed but
not documented at the protocol stage. For example, sys-
tematic reviewers may have assumed there was a specialty
consensus about which particular scale, intervention
Table 2 Primary and subgroup analyses for the PBI
PBI analyses
Number
of trials
Number of
meta-analyses PBI (95% CI*)
Primary analysis 118 31 0.57 (0.50 to 0.63)
Subgroup analyses
Availability of a systematic review protocol
With a protocol 27 12 0.55 (0.39 to 0.72)
Without a protocol 91 19 0.57 (0.49 to 0.65)
Subgroup difference†=−0.02 (95% CI −0.19 to 0.18; two-tailed p value of test of interaction 0.87)
Availability of a core outcome measurement set for the clinical condition of the review
Available core set (RA/OA systematic reviews) 55 15 0.62 (0.53 to 0.71)
No core set (depressive/anxiety disorder systematic
reviews)
63 16 0.51 (0.41 to 0.62)
Subgroup difference†=0.11 (95% CI −0.04 to 0.24; two-tailed p value of test of interaction 0.15)
*Percentile-based CIs for the PBI were constructed using bootstrap methods by resampling individual trials 2000 times.12
†The confidence limits and p value for the difference in PBI between subgroups was constructed using bootstrap methods from 2000
replicates.
OA, osteoarthritis; PBI, Potential Bias Index; RA, rheumatoid arthritis.
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dosage, time point or analysis to include in a review. In
this instance, we may have extracted trial effect estimates
that the reviewers considered ineligible. Further, we only
investigated selective inclusion of completely reported
effect estimates. The set of effect estimates that were
actually considered by the systematic reviewers may have
been larger, encompassing both reported and unre-
ported estimates (in the case of the latter, obtained dir-
ectly from the triallists). Empirical studies have found
that trial outcomes with unfavourable results are less
likely to be reported.14 15 Therefore, we may have under-
estimated the PBI if effect estimates with unfavourable
results were omitted from some of the trial reports, but
retrieved by the systematic reviewers and subsequently
excluded from the meta-analyses because of their
unfavourable results.
Explanations of study results
There are several possible reasons why the estimated PBI
was close to 0.5 (the value indicative of no selective
inclusion). It is possible that selective inclusion occurred
infrequently in this sample, and that the majority of sys-
tematic reviewers who did not report their selection
methods selected trial effect estimates based on factors
other than the magnitude and direction of the effects
(eg, based on some undisclosed clinical rationale).
Alternatively, our estimate of the PBI may be inﬂuenced
by the construction of the test statistic, which provides
Table 3 Number (%) of trials with multiplicity, number of possible meta-analytic standardised mean differences (SMDs), and
differences between meta-analytic SMDs for each index meta-analysis (n=31)
SR ID
Number
of trials
Number (%)
of trials with
multiplicity
Number of
meta-analytic
SMDs
Largest minus
smallest
meta-analytic
SMD
Index minus median
meta-analytic SMD*
Percentile rank
of index
meta-analytic
SMD†
1 2 2 (100) 6 0.34 0.16 0
2 6 3 (50) 24 0.09 −0.03 1
3 7 3 (43) 60 0.14 0.09 0.04
4 2 2 (100) 8 0.19 0.05 0.43
5 8 3 (38) 16 0.10 −0.01 0.53
6 3 1 (33) 2 0 0 0
7 5 1 (20) 2 0.03 0.01 0
8 20 10 (50) 3072 0.15 −0.05 0.95
9 7 1 (14) 3 0.04 −0.002 1
10 6 1 (17) 2 0.03 0.01 0
11 5 1 (20) 3 0.05 0 0.5
12 2 1 (50) 4 0.03 −0.02 1
13 2 1 (50) 2 0.04 −0.02 1
14 5 4 (80) 864 0.27 −0.09 0.93
15 13 11 (85) 2 239 488‡ 0.43 −0.06 0.76
16 3 1 (33) 2 0.01 −0.01 1
17 10 4 (40) 36 0.03 0.001 0.37
18 16 9 (56) 34 992‡ 0.11 0.03 0.05
19 3 1 (33) 3 0.18 −0.06 1
20 9 6 (67) 384 0.15 −0.06 0.98
21 5 1 (20) 3 0.01 −0.001 1
22 28 6 (21) 2304 0.10 −0.01 0.74
23 2 2 (100) 4 0.26 −0.10 0.67
24 5 3 (60) 24 0.19 −0.07 0.87
25 13 10 (77) 1 843 200‡ 0.39 −0.04 0.73
26 6 2 (33) 6 0.11 0.03 0.20
27 9 2 (22) 6 0.03 0 0.40
28 3 2 (67) 4 0.42 −0.20 1
29 20 18 (90) 1.8 trillion‡ 0.16 −0.03 0.85
30 21 4 (19) 576 0.03 0.01 0.01
31 4 2 (50) 576 0.28 −0.12 1
Median
(IQR)
6 (3, 10) 50% (22%, 67%) 8 (3, 576) 0.11 (0.03, 0.19) −0.01 (−0.05, 0.01) 0.74 (0.20, 1)
*Differences less than zero indicate that the index meta-analysis SMD is more favourable to the intervention compared with the median
meta-analytic SMD.
†When the percentile rank is 1, the index meta-analytic SMD was the most favourable of all possible meta-analytic SMDs.
‡For these meta-analyses, we generated a sampling distribution of 5000 meta-analytic SMDs. Each meta-analytic SMD was created by
randomly selecting (with equal probability) an effect estimate for inclusion from each trial, and meta-analysing the chosen effects.
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Figure 2 Range of possible
meta-analytic standardised mean
differences (SMDs) per index
meta-analysis, with median and
index meta-analytic SMD.
Figure 3 Meta-analysis of differences between the index meta-analytic SMD and median of all its possible meta-analytic SMDs
(each calculated using the random-effects model). Differences less than zero indicate that the index meta-analysis SMD is more
favourable to the intervention compared with the median meta-analytic SMD. ES, effect size; SMD, standardised mean
difference.
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more weighting to the rank position of effect estimates
when there are more available. The post hoc analysis
provides some evidence that when there are fewer effect
estimates, the PBI is larger. One hypothesis for this
result is that when there are only a few effect estimates,
the reviewer can more easily compare the effects and
select the most favourable, but when there are a large
number of effect estimates, this comparison is more dif-
ﬁcult, and so the reviewer selects effect estimates accord-
ing to some other factor which is unrelated to the
magnitude and direction. Contacting the authors to
conﬁrm the set of effect estimates they considered eli-
gible for inclusion, and the methods they used to select
effect estimates, could help rule out any suspected
selective inclusion.
The negligible impact of potential selective inclusion
on the meta-analytic effects may have been inﬂuenced
by several factors. These include the percentage of trials
with multiple effect estimates per meta-analysis, the
extent to which the multiple effect estimates in a trial
varied in magnitude and direction, the weights that trial
effect estimates received in the meta-analysis or any com-
bination of the above. For example, if one depression
scale yields an SMD of −0.2 and another yields an SMD
of −0.3, but the trial contributed little weight to the
meta-analysis, selective inclusion of the most favourable
SMD is unlikely to affect the meta-analysis in an import-
ant way. It would be useful to explore the association
between the above factors and the magnitude of bias
due to selective inclusion in future empirical studies.
Implications for systematic reviewers
We encourage systematic reviewers to predeﬁne methods
to select effect estimates to include in meta-analyses
despite the negligible impact of selective inclusion that
we found. Prespeciﬁcation of eligibility criteria and deci-
sion rules to select effect estimates provides transparency
in the review process and should make the process of
data extraction and analysis easier, because not all avail-
able effect estimates may need to be extracted.3 16
Current guidance documents recommend prespeciﬁca-
tion of eligibility criteria and decision rules for measure-
ment scales and time points.16–19 However, we believe
decision rules for other sources of multiplicity (eg,
unadjusted and covariate-adjusted analyses, analyses
undertaken on multiple samples such as intention-to-treat
and per-protocol) also deserve consideration.20 When
deciding which methods to prespecify, authors should
consider issues such as the measurement properties of
scales and clinical relevance of interventions and time
points. If available, established guidance (eg, core
outcome measurement sets or systematic reviews of the
psychometric properties of scales) can inform the choice
of methods to select effect estimates. Any rationale under-
lying the selection methods should be described in the
protocol.
At the review stage, we recommend that systematic
reviewers report the following: whether multiple trial
effect estimates were available for inclusion in particular
meta-analyses; if so, the methods used to select effect
estimates; and any post hoc additions, omissions or mod-
iﬁcations to methods to select effect estimates, along
with justiﬁcation for any discrepancies between the
review protocol and review. Reporting such information
may involve extra work for systematic reviewers, but will
certainly help readers assess the risk of selective inclu-
sion bias in meta-analyses. We recommend that a stan-
dardised table which facilitates reporting of information
on multiplicity and selection methods be developed.
Future research
It is important to investigate whether selective inclusion
of trial effect estimates occurs in meta-analyses which
address other clinical specialties than those examined in
our study. Most of the outcomes we examined were sub-
jective. It would be valuable to examine in future studies
mortality or other objective outcomes, which are not
free from the risk of selective inclusion bias as they can
be measured and analysed by triallists in multiple ways.
In addition, it would be useful to investigate whether
there is evidence of selective inclusion in meta-analyses
of dichotomous outcomes, which have some unique
types of multiplicity (eg, when events are deﬁned using
multiple diagnostic criteria, or deﬁned by dichotomising
measurement scales using different cut-points). Also,
rather than just investigating selective inclusion of results
fully reported in journal articles, it would be valuable to
explore the frequency of selective inclusion in reviews
with access to data in multiple sources (eg, conference
abstracts, regulatory documents, clinical study reports).
Further, given the evidence of an association between
industry funding and research outcomes,21 there is
beneﬁt in exploring whether selective inclusion is more
common in reviews funded by the sponsor of the product
under investigation. It would be ideal if future studies
adopt the methods we have used, so that the ﬁndings of
each investigation can be synthesised in meta-analyses.
CONCLUSION
There was no clear evidence that systematic reviewers
selectively included trial effect estimates in this sample
of meta-analyses of interventions for RA, OA, and
depressive or anxiety disorders. Any potential selective
inclusion did not have an important impact on the
meta-analytic effects. To enable readers to assess the risk
of selective inclusion bias, we recommend that systematic
reviewers report whether multiplicity of effect estimates
was encountered in trial reports, the methods used to
select effect estimates to include in meta-analyses, and
whether these methods were predeﬁned or developed
post hoc. Further research on selective inclusion in
other clinical specialties is needed.
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